Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028

ROCKET PHARMACEUTICALS, INC.

Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.
PRV was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel) for LAD-I.
Non-dilutive capital to support cardiovascular pipeline: Danon disease, PKP2-ACM, BAG3-DCM programs.
Cash runway extended into second quarter of 2028, per CEO Gaurav Shah.
PRV program reauthorized in February 2026, reinforcing incentive for rare pediatric disease therapies.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ROCKET PHARMACEUTICALS, INC. entered into PRV APA valued at $180 million (effective 2026-04-26).

Action: entry
Agreement: asset purchase
Value: $180 million
Effective: 2026-04-26

Exact text from the filing

On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).

View on SEC.gov

Browse all material agreements →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-26-017275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.